EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.

In this video, Xiuning Le, MD, PhD, discusses some of the latest developments in the study and treatment of EGFR-mutated lung cancer.

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in ...

Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with ...

The company recently presented the results of the phase 3 MARIPOSA study, looking at the combination of Rybrevant with Yuhan Corp-partnered Leclaza (lazertinib) as a first-line targeted therapy ...

with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first-line therapy for locally advanced and metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 ...

7 In January 2025, the European Commission (EC) approved a marketing authorisation for lazertinib, in combination with amivantamab, for the first-line treatment of adult patients with advanced ...

The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS ...